Dylan Wenke
Chief Business OfficerMr. Dylan Wenke is Chief Business Officer of CNS Pharmaceuticals, Inc. from March 2, 2026. Mr. Wenke serves as Vice President of Finance & Operations at EuMentis Therapeutics since 2024. He served as Head of Business Development at Corbus Pharmaceuticals Holdings, Inc since 2021. Mr. Wenke joined Corbus in May 2017 to create the business development function. He is responsible for corporate development, partnerships and collaborations. Throughout his time at Corbus he has driven several of the company’s key transactions, including the licensing agreement with Jenrin in 2018, the licensing agreement with Kaken in 2019 and the structured financing agreement with K2 HealthVentures in 2020. Before joining Corbus, Dylan served in business development roles at a venture backed start-up. He earned his B.Sc. in Chemistry from the University of North Florida.
Positions
- Company NameCNS Pharmaceuticals, Inc.Stock CodeCNSPPositionChief Business OfficerColleagues
- RLRami LevinPresident, CEO & Director
- FLFaith L. CharlesIndependent Chairman of Board
- SOSteve O’LoughlinChief Financial Officer
- EFEric FaulknerChief Technology Officer
- ELE. Lynne KelleyChief Medical Officer
- JRJeffry R. KeyesIndependent Director
- BMBettina M. CockroftIndependent Director
- AMAmy MaheryIndependent Director
